author-photo

Gamal Akabani

Duke University

34

Papers

2294

Citations

Citation Trend

Filter By

Papers (27) Sort By

Journal Conference Others

Overcoming Barriers to Radiopharmaceutical Therapy: An Overview from the NRG-NCI Working Group on Dosimetry of Radiopharmaceutical Therapy (RPT)

2020 International Journal of Radiation Oncology Biology Physics
Show All
- Source
- Cite
- Save
Citations (6)
Feasibility of Whole-Body Functional Mouse Imaging Using Helical Pinhole SPECT

2010 Molecular Imaging and Biology
Show All
- Source
- Cite
- Save
Citations (18)
Relationship of FDG-pet and mr perfusion imagingfindings in patients undergoing intracavitary radiation therapyfor intracerebral glioma

2008
Show All
- Source
- Cite
- Save
Citations (0)
A pilot study: 131I-Antitenascin monoclonal antibody 81c6 to deliver a 44-Gy resection cavity boost

2008 Neuro-oncology
Show All
- Source
- Cite
- Save
Citations (79)
Tumor resection cavity administered iodine-131-labeled antitenascin 81C6 radioimmunotherapy in patients with malignant glioma: neuropathology aspects.

2007 Nuclear Medicine and Biology
Show All
- Source
- Cite
- Save
Citations (13)
Clinical Experience with α-Particle–Emitting 211At: Treatment of Recurrent Brain Tumor Patients with 211At-Labeled Chimeric Antitenascin Monoclonal Antibody 81C6

2007 The Journal of Nuclear Medicine
Show All
- Source
- Cite
- Save
Citations (272)
Cell Therapy in Murine Atherosclerosis: In Vivo Imaging with High-Resolution Helical SPECT

2007 Radiology
Show All
- Source
- Cite
- Save
Citations (15)
Salvage Radioimmunotherapy With Murine Iodine-131–Labeled Antitenascin Monoclonal Antibody 81C6 for Patients With Recurrent Primary and Metastatic Malignant Brain Tumors: Phase II Study Results

2006 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (166)
Novel Human IgG2b/Murine Chimeric Antitenascin Monoclonal Antibody Construct Radiolabeled with 131I and Administered into the Surgically Created Resection Cavity of Patients with Malignant Glioma: Phase I Trial Results

2006 The Journal of Nuclear Medicine
Show All
- Source
- Cite
- Save
Citations (39)
In vitro cytotoxicity of 211At-labeled trastuzumab in human breast cancer cell lines: effect of specific activity and HER2 receptor heterogeneity on survival fraction.

2006 Nuclear Medicine and Biology
Show All
- Source
- Cite
- Save
Citations (52)